I believe ALKS will keep moving up and climb back over $22. Evidently analysts and investors were pleased with the corporate presentations. Not many bio-tech companies have proven products, stable earnings, and a solid pipeline. I wouldn't be surprised to see a big pharma take an interest in them. Either way, ALKS seems like one of the safer drug companies to own long term.